Cosentyx, manufactured by Novartis, contains the active ingredient secukinumab and is used to treat various inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis DrugPatentWatch.com.

Secukinumab's patent protection expired in 2023 DrugPatentWatch.com. However, due to regulatory requirements and pharmaceutical complexities, the availability of generic secukinumab might occur later than the patent expiration date.

As the U.S. Food and Drug Administration (FDA) typically requires a thorough review process and biosimilar approval for biologic drugs like secukinumab [1], it could take several years before generic alternatives can be prescribed as substitutes for Cosentyx.

Biosimilars, which are highly similar to the reference product (in this case, Cosentyx) and can work just as well, do not necessarily receive generic naming like traditional medications [2]. However, biosimilars can offer significant savings, particularly for patients who use these treatments long-term.

The exact timeline for generic secukinumab approval remains uncertain, and various factors can influence this process [3]. Healthcare providers and patients should keep an eye on FDA updates and seek professional advice on treatment options.

Sources:

1. https://www.fda.gov/drugs/biosimilars/biosimilar-product-development
2. https://www.americanacademy.org/biosimilars/biosimilar-product-definition
3. https://www.drugpatentwatch.com/cosentyx